Vaccines, an Undervalued and Underappreciated Medical Product:
will COVID-19 change this?

i3L power talk 2020

In this online lecture we will review the fundamentals of vaccine design, the importance of vaccine development as a public health tool, as vividly illustrated by the covid-19 pandemic and the promise of therapeutic vaccines in cancer therapy.


Date: Tuesday 1 December 2020
Time: 10:40 AM to 12:00 AM – WIB Time

Presented by CEO of Lipotek Pty Ltd, Ines I.C Atmosukarto Ph.D

Online Via Zoom 

zoom link will be sent through email

Register now: bit.ly/PowerTalki3L



Lipotek is a privately held Australian company (ABN 51 098 824 509) with laboratories and offices on the campus of the Australian National University. 

The company operates primarily as a research and development entity seeking to identify, protect, and commercialise adjuvant and delivery technologies to improve vaccine formulations.

The company seeks to demonstrate  ‘proof-of-concept’ for its Lipovaxin and Lipokel adjuvant platforms and aims to secure strategic alliances with biotech or pharmaceutical companies for the clinical development of selected products


× How can I help you?